MYC and cancer: Considering the extremely short half-lives of c-myc mRNA and protein [20], transcriptional inhibition induced by these analogues may be expected to more potently suppress c-myc expression in relation to other genes, thereby offering an alternative therapeutic approach to targeting this oncogene in cancer.